Aldeyra Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 131 HARTWELL AVENUE, LEXINGTON, MA, 02421
Mailing Address 131 HARTWELL AVENUE, LEXINGTON, MA, 02421
Phone 781-761-4904
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
-$55.85M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 5, 2025 | View on SEC |
| 8-K Current report of material events | October 28, 2025 | View on SEC |
| 8-K Current report of material events | August 19, 2025 | View on SEC |
| 4 Insider stock transaction report | August 15, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
| 4 Insider stock transaction report | August 13, 2025 | View on SEC |
Material Events
8-K Other December 16, 2025
High Impact
- The U.S. FDA has extended the review period for Aldeyra Therapeutics' dry eye drug, Reproxalap.
- This extension delays the potential approval and launch of Reproxalap, creating significant uncertainty for the company.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.